<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747197</url>
  </required_header>
  <id_info>
    <org_study_id>EYP-1901-001</org_study_id>
    <nct_id>NCT04747197</nct_id>
  </id_info>
  <brief_title>First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)</brief_title>
  <official_title>A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyePoint Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EyePoint Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label study to assess the bioactivity, ocular and systemic safety,&#xD;
      tolerability, and pharmacokinetics of a single injections of EYP-1901 at three dose levels:&#xD;
      440 µg, 2060 µg and 3090 µg&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ocular (study eye) and systemic treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Mean change in central retinal thickness on optical coherence tomography (OCT)</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean change in best corrected visual acuity (BCVA)</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Wet Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>EYP-1901 440 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EYP-1901 440 ug, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EYP-1901 2060 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EYP-1901 2060 ug, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EYP-1901 3090 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EYP-1901 3090 ug, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EYP-1901</intervention_name>
    <description>Intravitreal injection</description>
    <arm_group_label>EYP-1901 2060 ug</arm_group_label>
    <arm_group_label>EYP-1901 3090 ug</arm_group_label>
    <arm_group_label>EYP-1901 440 ug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects diagnosed with wet Age-Related Macular Degeneration (wAMD), in the study eye,&#xD;
             within 18 months before the Screening Visit.&#xD;
&#xD;
          -  Subject must have received ≥3 prior injections with the same anti-VEGF product:&#xD;
             bevacizumab, ranibizumab, or aflibercept) in the 6 months prior to the Screening&#xD;
             Visit, in the study eye.&#xD;
&#xD;
          -  Demonstrated response to the intravitreal anti-VEGF treatment in the study eye.&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) using ETDRS charts of 25 letters (20/320 Snellen&#xD;
             equivalent) to 75 letters (20/32 Snellen equivalent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for&#xD;
             AMD in the study eye.&#xD;
&#xD;
          -  Subfoveal fibrosis or scarring &gt;50% of the total lesion, or atrophy in the study eye,&#xD;
             confirmed by central reading center.&#xD;
&#xD;
          -  Choroidal neovascularization (CNV) in either eye due to other causes, such as ocular&#xD;
             histoplasmosis, trauma, or pathologic myopia that would compromise vision in the study&#xD;
             eye, confirmed by central reading center.&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye (e.g., cataract or glaucoma)&#xD;
             that, in the opinion of the Investigator, would either require surgical intervention&#xD;
             during the study to prevent or treat visual loss that might result from that condition&#xD;
             or affect interpretation of the study results.&#xD;
&#xD;
          -  Active intraocular inflammation (grade trace or above) in the study eye.&#xD;
&#xD;
          -  History of rhegmatogenous retinal detachment or treatment for retinal detachment or&#xD;
             macular hole (stage 3 or 4) in the study eye.&#xD;
&#xD;
          -  History of idiopathic or autoimmune-associated uveitis in either eye.&#xD;
&#xD;
          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either&#xD;
             eye.&#xD;
&#xD;
          -  History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery&#xD;
             in the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigative Site</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigative Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyePoint Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 6, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wAMD</keyword>
  <keyword>EYP-1901</keyword>
  <keyword>EyePoint</keyword>
  <keyword>DAVIO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

